USD
$0.00
(0.00%
)At Close (As of Sep 8, 2025)
$48.68B
Market Cap
53.1
P/E Ratio
0.29
EPS
$15.56
52 Week High
$12.51
52 Week Low
HEALTHCARE
Sector
Field | Value (JPY) |
---|---|
Gross Profit | $3T |
Total Revenue | $4.6T |
Cost Of Revenue | $1.6T |
Costof Goods And Services Sold | $1.6T |
Operating Income | $343B |
Selling General And Administrative | $1.1T |
Research And Development | $730B |
Operating Expenses | $2.7T |
Investment Income Net | - |
Net Interest Income | -$161B |
Interest Income | $182B |
Interest Expense | $137B |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $761B |
Income Before Tax | $175B |
Income Tax Expense | $67B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $108B |
Comprehensive Income Net Of Tax | - |
Ebit | $449B |
Ebitda | $1.2T |
Net Income | $108B |
Field | Value (JPY) |
---|---|
Total Assets | $14T |
Total Current Assets | $2.5T |
Cash And Cash Equivalents At Carrying Value | $385B |
Cash And Short Term Investments | $385B |
Inventory | $1.2T |
Current Net Receivables | $725B |
Total Non Current Assets | $12T |
Property Plant Equipment | $2T |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $3.6T |
Intangible Assets Excluding Goodwill | $3.6T |
Goodwill | $5.3T |
Investments | - |
Long Term Investments | $362B |
Short Term Investments | $20B |
Other Current Assets | $209B |
Other Non Current Assets | - |
Total Liabilities | $7.3T |
Total Current Liabilities | $2.5T |
Current Accounts Payable | $476B |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $549B |
Total Non Current Liabilities | $4.8T |
Capital Lease Obligations | - |
Long Term Debt | $4T |
Current Long Term Debt | $549B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $5.1T |
Other Current Liabilities | $1.5T |
Other Non Current Liabilities | $633B |
Total Shareholder Equity | $6.9T |
Treasury Stock | - |
Retained Earnings | $1.2T |
Common Stock | $1.7T |
Common Stock Shares Outstanding | $3.2B |
Field | Value (JPY) |
---|---|
Operating Cashflow | $1.1T |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $761B |
Capital Expenditures | $201B |
Change In Receivables | - |
Change In Inventory | -$35B |
Profit Loss | - |
Cashflow From Investment | -$367B |
Cashflow From Financing | -$751B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $302B |
Dividend Payout Common Stock | $302B |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$52B |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $108B |
Field | Value (JPY) |
---|---|
Gross Profit | $3T |
Total Revenue | $4.6T |
Cost Of Revenue | $1.6T |
Costof Goods And Services Sold | $1.6T |
Operating Income | $343B |
Selling General And Administrative | $1.1T |
Research And Development | $730B |
Operating Expenses | $2.7T |
Investment Income Net | - |
Net Interest Income | -$161B |
Interest Income | $182B |
Interest Expense | $137B |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $761B |
Income Before Tax | $175B |
Income Tax Expense | $67B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $108B |
Comprehensive Income Net Of Tax | - |
Ebit | $449B |
Ebitda | $1.2T |
Net Income | $108B |
Field | Value |
---|---|
Ex Dividend Date | 2025-03-31 |
Declaration Date | 2025-03-04 |
Record Date | 2025-03-31 |
Payment Date | 2025-07-07 |
Amount | 0.33901 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.